ai Custom silicon, open agents, and an IP lawsuit
Anthropic says Alibaba illicitly extracted Claude AI model capabilities
Anthropic alleged in a Reuters-reported filing that Alibaba illicitly extracted capabilities from the Claude AI model. The accusation drew 829 comments on Hacker News, making it the most-discussed item in the window. Anthropic did not detail the extraction method; the filing raised broad questions about IP protection for model weights and capabilities in an era of API access.
OpenAI unveils its first custom chip, built by Broadcom
OpenAI unveiled Jalapeño, its first custom inference chip, built in partnership with Broadcom. The chip is designed for inference rather than training and is intended to reduce OpenAI's reliance on Nvidia hardware. A custom ASIC for inference is a new category of asset for OpenAI; it allows the company to optimize silicon for its specific model architectures and control per-token costs at scale.
GLM-5.2 is the step change for open agents
Nathan Lambert argued that GLM-5.2 represents a genuine step change for open-source agents, calling it a capability threshold he had been watching carefully. GLM-5.2, released under a permissive license by Zhipu AI, performs at a level that Lambert says enables agent workflows that were previously only practical with closed frontier models. The claim follows a period of rapid open-weights releases from Chinese labs.
Computer use in Gemini 3.5 Flash
Google introduced computer use capabilities in Gemini 3.5 Flash, allowing the model to interact with desktop and web interfaces autonomously. The feature puts Gemini in direct competition with Claude's computer use offering. Flash's cost profile makes the capability more accessible for high-volume agentic workloads than prior implementations.
Qualcomm to Acquire Modular
Qualcomm agreed to acquire Modular, the company behind the Mojo programming language and the MAX inference engine, founded by Chris Lattner, who also created LLVM and Swift. The deal gives Qualcomm an AI software stack optimized for on-device and edge inference. Lattner confirmed the acquisition on social media. Financial terms were not disclosed.
I stopped trusting model benchmarks and started running my own eval set, here is what changed
A practitioner on r/MachineLearning stopped trusting published model benchmarks after noticing that Kimi K2.7 Code's headline gains were measured entirely on Moonshot's own benchmarks, with no independent corroboration. The post described building a private eval set instead and documented what changed: rankings shifted substantially, and several models that topped vendor charts fell in the author's task-specific tests. The thread drew broad discussion of benchmark contamination and incentive problems in model evaluation.
Prompt Injection as Role Confusion
A research team reframed prompt injection as role confusion rather than a content filtering failure. The argument is that models fail when they cannot distinguish between instructions from the operator and content from the environment; the fix requires architectural changes to how roles are represented, not just better filters. Simon Willison flagged the blog-style writeup as a clearer route to the paper's core claim.
Quoting Tom MacWright
Tom MacWright observed that job applications are now arriving with LLM-written cover letters linking to LLM-generated portfolio sites, which link to repositories with purely LLM-generated commit histories. Simon Willison quoted and amplified the observation. MacWright's concern is not the use of AI tools but the layered fabrication of a professional identity that has no authentic signal left for a hiring manager to read.
Why the Frontier Ecosystem must be Open; Matei Zaharia and Reynold Xin, Databricks
Databricks co-founders Matei Zaharia and Reynold Xin argued that the AI ecosystem's frontier must remain open for every company to build what they call Agent Clouds. Their case is that proprietary control over base models concentrates leverage in a way that prevents downstream companies from owning their own AI stacks. They described openness as an economic necessity for enterprise AI, not just a research preference.
45°C cooling design cuts data center water use to near zero
Nvidia published details on a data center liquid cooling design that raises coolant inlet temperature to 45°C, which allows the facility to reject heat passively to ambient air in most climates without evaporative cooling towers. The result is near-zero water consumption. The design trades marginally higher chip operating temperatures for the elimination of water infrastructure, a significant operational and siting advantage for AI factory deployments.
On the Theoretical Limitations of Embedding-Based Retrieval
Yannic Kilcher analyzed theoretical limitations of embedding-based retrieval systems, discussing fundamental constraints in how embeddings capture semantic relationships and what this means for RAG and search architectures.
Scientists Found A Better Language For AI Agents
Two Minute Papers covered research identifying better formal languages for AI agent task planning, with evidence that how agents represent intentions to themselves affects execution reliability and success rates.
Europe is noping out of AI lmao
Mo Bitar examined Europe's regulatory approach to AI, covering how export controls and compliance requirements are reshaping development incentives and pushing capability building toward Asia.
OpenAI's 2025 financials LEAKED
Mo Bitar reported leaked OpenAI 2025 financial data, examining revenue trajectories and burn rates that frame the company's path to profitability and competitive position versus other labs.
I had Fable build several projects for me. I'm disturbed by what I saw.
Mo Bitar tested Fable AI on project building, documenting quality issues and reliability gaps when the model executes multi-step development tasks without human oversight.
DeepSeek Just Solved AI's Billion Dollar Problem
Two Minute Papers reported on DeepSeek's progress on reducing inference costs, covering algorithmic and hardware changes that lower per-token expenses by an order of magnitude.
[AINews] It's Meta-Harness Summer
Latent Space covered meta-harness summer, documenting the proliferation of agentic frameworks and orchestration tooling as teams build abstractions on top of frontier models.
Thinking to recall: How reasoning unlocks parametric knowledge in LLMs
Google Research documented how explicit reasoning steps in language models unlock parametric knowledge, showing that test-time compute applied to recall tasks improves factual accuracy.
Accelerating Transformers Fine-Tuning with NVIDIA NeMo AutoModel
NVIDIA and Hugging Face documented NeMo AutoModel for transformer fine-tuning, covering distributed training optimizations that reduce time to adapt models for downstream tasks.
software Chip deals, PR spam, and a post-quantum deadline
PR spam today looks like email spam in the early 2000s
Greptile, which operates a code review service, reported that pull request spam on its open-source repositories now resembles email spam in the early 2000s: high volume, low quality, and generated automatically. The company described bots opening hundreds of PRs with trivial or fabricated changes, often citing AI-generated justifications. The pattern suggests that agentic coding tools are being deployed for reputation farming and contribution fraud at scale.
The post-quantum EO is an important milestone. Now it's time to get to work
A White House executive order set a 2030 deadline for federal agencies and contractors to migrate to post-quantum cryptography. Cloudflare assessed the order as a meaningful milestone while noting gaps: it does not establish mandatory timelines for private critical infrastructure, and many organizations lack the inventory of cryptographic assets needed to plan a migration. Cloudflare published its own migration playbook alongside the analysis.
Slow down to speed up: so much has changed in 6 months' time
The Pragmatic Engineer surveyed what has changed in software engineering over the first half of 2026: AI coding tools have become standard at most large tech companies, some organizations are deliberately slowing adoption to absorb earlier changes, and the definition of a software engineering role is shifting faster than hiring pipelines can adapt. The issue argued that slowing down to consolidate practices may be the more productive near-term strategy for many teams.
Unlocking the Cloudflare app ecosystem with OAuth for all
Cloudflare made Self-Managed OAuth available to all developers on its platform, completing a zero-downtime migration of its core OAuth engine. The change lets third-party applications authenticate against Cloudflare without requiring Cloudflare-issued API tokens. The migration involved replacing internal session management infrastructure while keeping existing integrations live throughout.
How we found a bug in the hyper HTTP library
Cloudflare engineers found a bug in the hyper HTTP library, an open-source Rust crate widely used for HTTP client and server implementations, while rearchitecting the Workers Images binding. The bug affected multiple major versions and had been present for years. Cloudflare reported the issue to the hyper maintainers and documented the conditions under which the bug triggers.
simonw/browser-compat-db
Simon Willison converted Mozilla's mdn/browser-compat-data repository into a SQLite database and published it as a new GitHub project, simonw/browser-compat-db. The conversion was prompted by Mozilla's new MDN MCP service. The SQLite format allows the full compatibility dataset to be queried locally or via Datasette without parsing the underlying JSON files.
pharma GLP-1 costs spike U.S. health spending; Ebola trial begins
U.S. health spending rose sharply in 2025, thanks to GLP-1 use and more care
U.S. health care spending rose 7.3% in 2025, reaching roughly $6 trillion, according to data reported by STAT. GLP-1 drugs for obesity and diabetes were a primary driver alongside higher overall care utilization. The increase reversed a multi-year trend of moderate spending growth and raised projections for federal health program costs over the next decade.
Clinical trial set to test two drugs for fast-growing Ebola outbreak
A clinical trial testing two drugs against Bundibugyo ebolavirus is set to begin next week in Central Africa, WHO officials said. The trial will test Gilead's remdesivir and MappBio's MBP-134 against a fast-moving outbreak. Bundibugyo is one of the less common Ebola species and has had fewer treatment trials than Zaire ebolavirus, which drove the major West African outbreak.
Bipartisan bill seeks to allow direct prescribing of methadone for opioid addiction
A bipartisan bill introduced in the Senate would allow physicians to prescribe methadone for opioid use disorder directly, bypassing the current requirement that patients receive the drug only at federally certified opioid treatment programs. Under existing rules, patients must attend a clinic in person, often daily in early treatment. The bill would extend methadone access through standard pharmacies, aligning it more closely with buprenorphine prescribing.
Biosecure didn't stop China's rise in biotech. Some lawmakers want to do more
U.S. lawmakers are drafting legislation to counter China's growing presence in the biotech industry after the Biosecure Act stalled. STAT reported that the new proposals target Chinese contract research and manufacturing organizations more directly, imposing earlier compliance deadlines and broader restrictions on U.S. federal funding for companies with Chinese ties. China has built a large position in drug manufacturing and genomics infrastructure since the Biosecure debate began.
Facing a brutal run, battered vaccine makers still see cause for hope
Vaccine makers gathered at the BIO conference this week described the current period as one of the most difficult in the industry's recent history, with reduced government procurement commitments, lingering public skepticism, and pipeline attrition. Executives said they still see cause for optimism in mRNA platform flexibility and the pipeline of infectious disease targets, but acknowledged that near-term revenue visibility is lower than at any point since the pandemic.
Judge temporarily blocks subpoenas in criminal probe of transgender care at New York hospitals
A federal judge temporarily blocked Department of Justice subpoenas seeking medical records of transgender patients treated at two New York hospitals. Prosecutors in Texas had sought the records as part of a criminal investigation. The judge's order prevents access while the legal challenge proceeds; it is one of the first rulings to directly constrain DOJ's use of subpoenas in the federal campaign against gender-affirming care.
Another roadblock for DOJ campaign against trans health
A judge in New York temporarily blocked federal prosecutors from accessing medical records of transgender patients treated at state hospitals, stalling a criminal investigation into gender-affirming care protocols.
STAT+: Facing a brutal run, battered vaccine makers still see cause for hope
Vaccine manufacturers facing a brutal commercial stretch due to weak demand and competition from lower-cost alternatives reported some causes for optimism including RSV vaccines and updated COVID formulations.
Opinion: My adult daughter has Down syndrome. Her life is entirely different from what experts expected
Michelle Sie Whitten of the Global Down Syndrome Foundation argued that meaningful choice in prenatal diagnosis requires vetted information and that life expectancy and health outcomes for Down syndrome have improved substantially.
Bipartisan bill seeks to allow direct prescribing of methadone for opioid addiction
A bipartisan bill would allow methadone to be prescribed and dispensed at pharmacies rather than specialty clinics, expanding access for opioid addiction treatment and reducing logistical barriers.
STAT+: Biosecure didn't stop China's rise in biotech. Some lawmakers want to do more
Lawmakers are laying groundwork for legislation and regulation to counter Chinese biotech companies, viewing the Biosecure Act as insufficient to slow Chinese advancement in drug discovery and manufacturing.
Opinion: How a 1976 murder case changed doctor-patient confidentiality
A bioethicist examined the Tarasoff case at its 50th anniversary, analyzing how a 1976 murder case reshaped doctor-patient confidentiality law and continues to influence psychiatric practice.
STAT+: Eli Lilly dives into hair loss treatments with investment in AI startup Absci
Eli Lilly is investing in Absci, an AI startup developing a hair-growth drug and potential endometriosis treatment, expanding the pharmaceutical giant's biopharma venture portfolio.
STAT+: U.S. health spending rose sharply in 2025, thanks to GLP-1 use and more care
U.S. healthcare spending rose 7.3 percent in 2025 to reach 5.7 trillion dollars, driven partly by increased GLP-1 drug use and expanded access to medical services across populations.
Judge temporarily blocks subpoenas in criminal probe of transgender care at New York hospitals
A federal judge in New York blocked prosecutors in Texas from obtaining medical records of transgender patients treated at New York hospitals, citing constitutional privacy concerns.
Clinical trial set to test two drugs for fast-growing Ebola outbreak
WHO said a clinical trial testing Gilead's remdesivir and MappBio's MBP-134 against Bundibugyo ebolavirus will begin next week amid a fast-moving outbreak in Central Africa.
STAT+: A dispatch on AI from BIOtech's big summer bash
STAT reported from BIO on how biotech companies are approaching artificial intelligence, documenting strategy shifts toward AI-native drug discovery and deployment.
STAT+: AI wades into a vexing medical mystery: What causes sudden cardiac death?
A new Nature study used machine learning to identify people at high risk for sudden cardiac death and pinpointed possible biological mechanisms, opening new avenues for risk stratification.
healthtech AI reads cardiac risk; AI at BIO; whole-body screening debate
AI wades into a vexing medical mystery: What causes sudden cardiac death?
A study published in Nature used an AI model trained on electrocardiograms and cardiac imaging to identify patients at elevated risk of sudden cardiac death and pinpoint a structural feature that may explain it. The model outperformed existing clinical scoring tools in the study cohort. Sudden cardiac death has resisted prediction because most victims have no prior diagnosis; the AI approach identified a subgroup missed by conventional risk stratification.
A dispatch on AI from BIOtech's big summer bash
At the BIO conference, biotech companies described AI as having moved from a feature to a requirement in drug discovery pipelines. STAT's Brittany Trang reported that companies are no longer asking whether to use AI but how to integrate it across target identification, molecular design, and clinical trial optimization. Several executives said the pressure to show AI adoption is now coming from investors, not just scientists.
Eli Lilly dives into hair loss treatments with investment in AI startup Absci
Eli Lilly invested in Absci, an AI drug design startup, to develop a treatment for hair loss with potential applications in endometriosis. Absci uses generative biology to design protein-based therapeutics. Hair loss is a large consumer market that major pharma has historically underserved; the endometriosis angle suggests a hormonal mechanism that could support a broader indication.
Should People Avoid Whole-Body Screening Info?
Scott Alexander examined whether people should seek out whole-body MRI screening given the current state of evidence. He assessed the case for and against elective scanning, weighing the probability of catching a treatable condition early against false positive rates, downstream testing costs, and incidentaloma anxiety. His conclusion was conditional: the calculus depends heavily on individual risk factors and whether the scanner uses a validated protocol with a radiologist experienced in incidentaloma interpretation.